
|Poll|December 21, 2022
POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Author(s)Dermatology Times Staff
Click here to answer this week's poll.
Advertisement
Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5

















